Breaking News
Subscribe Now 0
🧐 ProPicks AI October update is out now! See which stocks made the list Pick Stocks with AI
Close

Edesa Biotech Inc (EDSA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Edesa Biotech's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.2700 -0.4100    -8.76%
03/10 - Closed. Currency in USD ( Disclaimer )
After Hours
4.7000
+0.4300
+10.0703%
16:02:51 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 32,172
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 4.2000 - 4.5400
Edesa Biotech 4.2700 -0.4100 -8.76%

Edesa Biotech Inc Company Profile

 
Get an in-depth profile of Edesa Biotech Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

16

Equity Type

ORD

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Contact Information

Address 100 Spy Court
Markham, L3R 5H6
Canada
Phone 289 800 9600
Fax -

Top Executives

Name Age Since Title
Pardeep Nijhawan 51 2019 CEO, Company Secretary & Director
Sean Arthur MacDonald 47 2019 Independent Director
Carlo Sistilli 66 2019 Independent Chairman of the Board
Patrick Jeffrey Marshall 53 2023 Independent Director
Charles V. Olson 67 2023 Independent Director
Frank R. Oakes 74 2010 Independent Director
Joan Chypyha 57 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EDSA Comments

Write your thoughts about Edesa Biotech Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mauricio Castillo
Mauricio Castillo Aug 23, 2024 10:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this stock is complicated, good reviews good numbers after hours it projects good numbers but during the day, it does not move
Jean Mercredi
Jean Mercredi Oct 13, 2023 9:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What happened?
Nhat Doan
Nhat Doan Dec 23, 2022 10:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
👉 TEST 👉 Can Not SHORT NEVER BUY - DELETE
Jean Mercredi
Jean Mercredi May 31, 2022 8:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What's the news?
Miami Transport inc
Miami Transport inc Sep 21, 2021 3:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buying the dip
Jean Mercredi
Jean Mercredi Sep 21, 2021 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buying the dip
colf Wat
colf Wat Dec 03, 2020 11:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Damn it. I got bitten here! ****stock
Josh Parker
Josh Parker Aug 31, 2020 6:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Losing money i hope it goes up in phase 3
Precocious Crissy
Precocious Crissy Jul 30, 2020 10:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
in at 7.30 out at 16.23. good stuff. a month waiting
Nison Kay
Nison Kay Jul 30, 2020 10:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
don't be a dik
adam adam
adam adam Jul 30, 2020 9:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
super bomb
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email